Physician profile
Cherie Shuler
NPI 1760062301
$1,845.59
in general payments reported to CMS, 2019-2025
28 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $618 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.86 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $172.38 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $154.22 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.73 | 2024-2025 | |
| Glaxosmithkline, LLC. | $121.78 | 2024-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $85.21 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $76.56 | 2024-2025 | Ozempic, Rybelsus |
| Corium, LLC | $61.42 | 2024 | Azstarys |
| Amgen INC. | $61.34 | 2024-2025 | Repatha, Repatha |
| Radius Health, INC. | $55.47 | 2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $48.49 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.12 | 2025 | Caplyta |
| Exact Sciences Corporation | $46.07 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $45.78 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.16 | 2024 | Xifaxan, Trulance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $40.80 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $39.76 | 2024-2025 | Rexulti |
| Corcept Therapeutics | $34.76 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $34.12 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $31.62 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2024 | Jardiance |
| Vanda Pharmaceuticals INC. | $30.36 | 2025 | Fanapt |
| Tandem Diabetes Care, INC. | $26.37 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $26.19 | 2025 | |
| Shield Therapeutics INC | $24.07 | 2025 | |
| Lundbeck LLC | $20.08 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $19.58 | 2025 | Spravato |
| Aimmune Therapeutics, INC. | $19.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherie Shuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.